Actively Recruiting
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Led by British Columbia Cancer Agency · Updated on 2024-08-09
10
Participants Needed
1
Research Sites
145 weeks
Total Duration
On this page
Sponsors
B
British Columbia Cancer Agency
Lead Sponsor
U
University of Texas Southwestern Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.
CONDITIONS
Official Title
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of ovarian cancer
- Any stage or grade of ovarian cancer
- Presence of ascites fluid that requires drainage
- Any treatment regimen allowed
- Includes both primary and recurrent ascites
- Ability to understand the study and provide informed consent
You will not qualify if you...
- Diagnosis of diabetes or abnormal hemoglobin A1C levels
- Blood glucose levels outside the range of 4 to 11.1 mM before infusion
- Receiving chemotherapy treatment during the 5-hour duration of the experiment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jennifer Rauw
Victoria, British Columbia, Canada
Actively Recruiting
Research Team
J
Julian J. Lum, PhD
CONTACT
J
Jennifer Rauw, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here